FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068239602> ?p ?o ?g. }

• W2068239602 endingPage "489" @default.
• W2068239602 startingPage "475" @default.
• W2068239602 abstract "Free AccessCPAPEffect of Obstructive Sleep Apnea Hypopnea Syndrome on Lipid Profile: A Meta-Regression Analysis Rashid Nadeem, M.D., Mukesh Singh, M.D., Mahwish Nida, MB.BS., Irfan Waheed, M.D., Adnan Khan, M.D., Saeed Ahmed, M.D., Jawed Naseem, M.Sc., Daniel Champeau, M.S. Rashid Nadeem, M.D. Address correspondence to: Rashid Nadeem, M.D., Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, Illinois, 60064(847) 578-3000(866) 239-8451 E-mail Address: [email protected] Rosalind Franklin University of Medicine and Science,Chicago Medical School, North Chicago,IL Search for more papers by this author , Mukesh Singh, M.D. Department of Cardiology, James A Lovell Federal Health Care Center, North Chicago, IL Search for more papers by this author , Mahwish Nida, MB.BS. Rematul lil Alameen Institute of Cardiology, Lahore, Pakistan Search for more papers by this author , Irfan Waheed, M.D. Rosalind Franklin University of Medicine and Science,Chicago Medical School, North Chicago,IL Search for more papers by this author , Adnan Khan, M.D. Rosalind Franklin University of Medicine and Science,Chicago Medical School, North Chicago,IL Search for more papers by this author , Saeed Ahmed, M.D. New York University, New York,NY Search for more papers by this author , Jawed Naseem, M.Sc. University of Karachi, Karachi, Pakistan Search for more papers by this author , Daniel Champeau, M.S. Rosalind Franklin University of Medicine and Science,Chicago Medical School, North Chicago,IL Search for more papers by this author Published Online:May 15, 2014https://doi.org/10.5664/jcsm.3690Cited by:91SectionsAbstractPDF ShareShare onFacebookTwitterLinkedInRedditEmail ToolsAdd to favoritesDownload CitationsTrack Citations AboutABSTRACTBackground:Obstructive sleep apnea (OSA) is associated with obesity, metabolic syndrome, and dyslipidemia, which may be related to decrease androgen levels found in OSA patients. Dyslipidemia may contribute to atherosclerosis leading to increasing risk of heart disease.Methods:Systematic review was conducted using PubMed and Cochrane library by utilizing different combinations of key words; sleep apnea, obstructive sleep apnea, serum lipids, dyslipidemia, cholesterol, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and triglyceride (TG). Inclusion criteria were: English articles, and studies with adult population in 2 groups of patients (patients with OSA and without OSA). A total 96 studies were reviewed for inclusion, with 25 studies pooled for analysis.Results:Sixty-four studies were pooled for analysis; since some studies have more than one dataset, there were 107 datasets with 18,116 patients pooled for meta-analysis. All studies measured serum lipids. Total cholesterol pooled standardized difference in means was 0.267 (p = 0.001). LDL cholesterol pooled standardized difference in means was 0.296 (p = 0.001). HDL cholesterol pooled standardized difference in means was -0.433 (p = 0.001). Triglyceride pooled standardized difference in means was 0.603 (p = 0.001). Meta-regression for age, BMI, and AHI showed that age has significant effect for TC, LDL, and HDL. BMI had significant effect for LDL and HDL, while AHI had significant effect for LDL and TG.Conclusion:Patients with OSA appear to have increased dyslipidemia (high total cholesterol, LDL, TG, and low HDL).Citation:Nadeem R, Singh M, Nida M, Waheed I, Khan A, Ahmed S, Naseem J, Champeau D. Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med 2014;10(5):475-489.INTRODUCTIONObstructive sleep apnea (OSA) is a common disorder affecting about 4% of middle-aged males and 2% of middle-aged women in the developed world and is a significant source of morbidity and mortality.1,2 OSA is characterized by recurrent episodes of upper airway collapses during sleep. These recurrent episodes of upper airway collapse usually are accompanied by oxyhemoglobin desaturation and terminated by brief arousals which result in marked sleep fragmentation and chronic excessive daytime sleepiness (EDS).1,2OSA has been increasingly linked to cardiovascular and cerebrovascular disease, and many studies have shown that OSA is associated with increased cardiovascular and cerebrovascular morbidity.3–9 OSA is associated with obesity and metabolic syndrome.10 Multiple studies addressing this interesting and complex issue are available where lipid profile was measured in subjects with OSA.11–35 We performed meta-analysis (MA) and meta-regression (MR) to specifically detect if OSA adversely affects degree of dyslipidemia; elevation of total cholesterol (TC), low density lipoprotein cholesterol (LDL), triglyceride (TG), and reduces level of high density lipoprotein cholesterol (HDL).BRIEF SUMMARYCurrent Knowledge/Study Rationale: Dyslipidemia (increase in total cholesterol, LDL, and triglycerides, and decrease in HDL) and obstructive sleep apnea (OSA) are risk factors for cardiovascular and cerebrovascular disorders. This meta-regression analysis estimates the adverse effect of OSA on dyslipidemia as many studies have measured dyslipidemia in subjects with OSA.Study Impact: Study suggests dyslipidemia may be the mechanism of atherosclerosis in subjects with OSA. It also suggests OSA as potential target for treatment to improve dyslipidemia for prevention and treatment for cardiovascular and cerebrovascular disease.METHODSData Source and Study SelectionStudies for review were found searching the PubMed, Cochrane, and EMBASE databases from January 01, 1968, to November 30th, 2013. Unpublished data from scientific meetings were not searched, since most abstract do not provide detail raw data needed for meta-analysis. Searches were conducted using the keywords; sleep apnea, obstructive sleep apnea, serum lipids, dyslipidemia, cholesterol, total cholesterol, low density lipoprotein, high density lipoprotein, and triglyceride. Each target outcome was also searched in its abbreviated forms (Chol T, HDL, LDL, and TG) to ensure that no relevant source was left out. Additionally, each target and its abbreviated forms were searched in combination with obstructive sleep apnea. Multiple authors individually searched for and scored manuscripts for inclusion. If manuscripts scored differently by 2 authors then it was reviewed by third author to finalize its inclusion.Studies and Endpoint DefinitionsLipid profile includes total cholesterol (TC), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), and triglyceride (TG). Inclusion criteria defined for subsequent study selection were as follows: (1) the study must be in English, (2) studies with adult population only, (3) full-text manuscripts had to be available, (4) the study must have reported values for at least one of the outcome of interest, (5) the study must have included ≥ 2 separate groups with one being a group consisting of individuals with obstructive sleep apnea and the other consisting of individuals without obstructive sleep apnea, (6) OSA was defined as AHI ≥ 5/h, (7) the study must have reported values in mean and standard deviation or median with range, and (8) patient number for all groups must have been reported.Data Extraction and Statistical AnalysisStudies identified for inclusion then underwent data extraction. Data was extracted at a study level by a single author and then reviewed by a second author to ensure no errors were made. Levels of serum lipids were extracted from studies as mean with standard deviation. For studies with data reported in median and range, mean and standard deviation were calculated utilizing methods outlined by Hozo et al.36For studies in which OSA patients were compared with more than one group of control patients (e.g., obese and lean control), each set of data in the study was included in the meta-analysis as a separate data set. For example, Barcelo et al. compared lipid profiles of obese OSA patients and non-obese OSA to healthy controls.11 We used standardized differences in means method for analyzing extracted data from studies.Study selection, data extraction, and statistical analysis were all done in accordance to previously published methodology for meta-analyses. All statistical analysis was done using Comprehensive Meta-Analysis Version 2.Heterogeneity was assessed by calculating the Cochrane Q statistic. Additionally I2 statistics was also calculated to assess heterogeneity. An I2 of 25% to 49% was considered to represent a low level of heterogeneity, 50% to 60% a moderate level, and 60% to 100% a high level. Standardized differences in mean were calculated using a random effects model for all outcomes with > 60% heterogeneity (I2 > 60) and fixed effect model for I2 < 60. Measurement unit of lipid profile was mmol/L. If any of these values were in mg/dL they were converted into mmol/L by dividing them by their molar weight. Publication bias analysis was done using four different methods to provide robust results. The methods included funnel plot analysis, Eggers reg intercept, Duval and Tweedie trim and fill, and Kendall tau with and without continuity correction.RESULTSThe literature was ranked according to the hierarchy of evidence of Sackett et al.37 A total of 96 studies were reviewed for inclusion. Sixty-four studies (with 107 datasets) met inclusion criteria and pooled for meta-analysis including total subjects 18,116 (controls [N = 10,145] and OSA subjects [N = 7,971]) for analysis (Figure 1).Figure 1: Flow diagram for search and inclusion and exclusion of studiesDownload FigureTotal CholesterolA total of 63 studies with 107 datasets including 18,111 subjects were pooled for TC. Standardized differences in means ranged from −2.05 to 5.0; pooled mean difference was calculated to be 0.267 (lower limit [LL] 0.146 to upper limit [UL] 0.389, p value = 0.001; see appendix following references, Figure A1).LDL CholesterolFor LDL, 50 studies with 82 datasets including 13,894 subjects were pooled. Standardized mean difference in LDL ranged from −1.679 to 3.243, pooled mean difference was calculated to be 0.296 (LL 0.156 to UL 0.436, p = 0.001; Figure A2)HDL CholesterolFor HDL, 64 studies with 107 datasets including 18,116 subjects were pooled. Standardized mean difference ranged from −17.96 to 2.364. The pooled mean difference was calculated to be −0.433 (LL −0.604 to UL −0.262, p < 0.001; Figure A3).TriglycerideFor TG, 62 studies with 104 datasets including 17,831 subjects were pooled and analyzed. Standardized mean difference ranged from −2.476 to 15.206, pooled mean difference was calculated to be 0.603 (LL 0.431 to UL 0.775, p < 0.001; Figure A4).Meta-Regression to evaluate the effect of Age, BMI, and AHI on Lipid LevelsData was also analyzed by meta-regression for effect of age, BMI, and AHI on all 4 variables of interest. Results of this analysis are given in Table 1. Age had significant effect for TC, LDL, and HDL. BMI had significant effect for LDL and HDL, while AHI had significant effect for HDL and TG (Figures 2–4). Only AHI had significant effect for TG.Table 1 Meta Regression statistics for Lipids (TC, LDL, HDL, TG) for Age, BMI, and AHITable 1 Meta Regression statistics for Lipids (TC, LDL, HDL, TG) for Age, BMI, and AHIFigure 2: Meta-regression plots for age on TC, LDL, HDL, and TGDownload FigureFigure 3: Meta-regression plots for BMI on TC, LDL, HDL, and TGDownload FigureFigure 4: Meta-regression plots for AHI on TC, LDL, HDL, and TGDownload FigurePublication Bias AnalysisPublication bias analysis was done using four different methods to provide robust results. The methods included funnel plot analysis (Figure 5), Eggers reg intercept, Duval and Tweedie trim and fill, and Kendall tau with and without continuity correction. Overall, there was no significant publication bias in combined analysis. We also performed this analysis for individual lipid components and this analysis showed that there is low likelihood of publication bias for TC, TG, and LDL-c. HDL-c analysis showed likelihood of publication bias. We also performed precision plots (Figure 6).Figure 5: Publication bias estimation, Funnel plots for TC, LDL, HDL, and TGDownload FigureFigure 6: Precision plot analysesDownload FigureSensitivity AnalysisWe also performed sensitivity analysis by removing one study at each step that did not change results, and it makes our results more robust (Figures A5–A8).DISCUSSIONThere is strong positive associations between low-density lipoprotein (LDL) particles, which carry cholesterol, and the risk of coronary heart disease (CHD).38,39 Randomized trials have demonstrated that lowering LDL cholesterol with medications reduces the risk of cardiac death, nonfatal myocardial infarction (MI), ischemic stroke, and the need for revascularization procedures.40–42Although a clear causal relationship of OSA and dyslipidemia is yet to be demonstrated, there is increasing evidence that chronic intermittent hypoxia, a major component of OSA, is independently associated and possibly the root cause of the dyslipidemia via the generation of stearoyl-coenzyme A desaturase-1 and reactive oxygen species, peroxidation of lipids, and sympathetic system dysfunction.43 Intermittent hypoxia associated with sleep apnea promotes oxidative, and immune-inflammatory alterations.44 Systemic inflammatory markers are higher in OSA patients than control subjects.45 Cytokines, specifically IL-1, may alter LDL metabolism by human vascular endothelial cells and alter endothelial cell cholesterol metabolism. These changes in endothelial cell metabolism provide evidence supporting the critical role of cytokines in atherogenesis.46The present meta-analysis (MA) showed that there is an increase in levels of dyslipidemia in subjects with OSA including total cholesterol, low density lipoprotein, high density lipoprotein, and triglyceride. An obvious majority of studies11–26,31–35 showed this effect, while few did not.27,30,31 Ozol et al. found less dyslipidemia in patients with moderate OSA than controls, most likely because their controls have high insulin resistance measured by HOMA and higher insulin levels than moderate OSA patients.27 Moreover they found a high degree of dyslipidemia in their mild and severe OSA groups, which suggest that confounding factors may have played a role in their subjects' lipid levels (hypertension, obesity, and frequency of metabolic syndrome) in their sample. Another study which did not show significant dyslipidemia in OSA was by Salord et al. Their small sample (OSA, n = 15 and control n = 12) had unique characteristics: all controls without OSA were significantly obese (BMI 46.9) undergoing bariatric surgery.31 Moreover their OSA patients were being treated with CPAP, which may explain the different findings of the study.These findings highlight the adverse role of OSA as risk factor for cardiovascular diseases. These finding also suggest that increasing dyslipidemia may also be the mechanism of atherosclerosis in patients with OSA. It provides a potential target for treatment of dyslipidemia. Conceivably there is data suggesting that treatment of OSA by CPAP improves dyslipidemia, atherosclerosis and cardiovascular disease.47Meta-regression Analysis for Confounding VariablesThese MR plots show that dyslipidemia (HDL and TG) is correlated by severity of OSA, higher the AHI the higher the dyslipidemia. Gasa et al.19 show that level of dyslipidemia correlates well with the severity of OSA; gradual worsening with worst numbers found in severe OSA group. Their regression analysis showed beta of 0.007 for TG. Likewise, Peled et al. found dyslipidemia in their sample as follow; control < mild OSA < severe OSA < moderate OSA30. Their Beta coefficient was 0.332 for AHI, which suggests that this relationship is probably confounded by multiple factors including weight, BMI, and comorbid conditions.These MR plots also showed the modest but significant effect of BMI on dyslipidemia (LDL and HDL). This is in agreement with many other studies. Sharma et al. showed that BMI had an independent association with OSA.This finding of heightened dyslipidemia in patients with obstructive sleep apnea suggest that treatment of sleep apnea should improve this risk factors for heart disease directly or indirectly by affecting other confounding factors (obesity, hypertension, diabetes mellitus, and metabolic syndrome), as CPAP treatment for sleep apnea has been shown to positively affect management of these confounding variables.48–51Several limitations of this meta-analysis should be emphasized. Available literature is low level evidence. Many of the relevant studies regarding the association between OSA and level of dyslipidemia were cross-sectional in nature, so the temporal relationships between these two factors were unclear. Funnel plots suggest heterogeneity and publication bias (Figure 5). We could not perform the meta-regression for other confounding factors—sleepiness, presence of hypertension, or measures of visceral adipose tissue—since we have data on these variables only in few studies. These factors have been found to be associated with elevated dyslipidemia.One weakness of our meta-analysis is that all papers written in languages other than English were excluded. Another weakness is that studies not yet published were also excluded (publication bias).In summary, there appears to be some evidence indicating higher degree of dyslipidemia in patients with OSA, these levels may be correlated to the level of severity of disease as suggested by meta-regression plot for AHI. These findings may explain, at least in part, the mechanism for atherosclerosis leading to cardiovascular disorder in patients with OSA and the common occurrence of systemic complications among these patients. Future studies are needed to further explore the correlation between the level of dyslipidemia and severity of OSA and to determine whether levels of dyslipidemia can be modified by therapeutic interventions in these patients.DISCLOSURE STATEMENTThis was not an industry supported study. The authors have indicated no financial conflicts of interest.REFERENCES1 Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr SThe occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med; 1993;32:1230-5, 8464434. CrossrefGoogle Scholar2 Guilleminault C, Tilkian A, Dement WCThe sleep apnea syndromes. Annu Rev Med; 1976;27:465-84, 180875. CrossrefGoogle Scholar3 Nieto FJ, Young TB, Lind BKet al.Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA; 2000;283:1829-36, 10770144. CrossrefGoogle Scholar4 Peppard PE, Young T, Palta Met al.Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med; 2000;342:1378-84, 10805822. CrossrefGoogle Scholar5 Shahar E, Whitney CW, Redline Set al.Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med; 2001;163:19-25, 11208620. CrossrefGoogle Scholar6 Peker Y, Hedner J, Norum J, Kraiczi H, Carlson JIncreased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med; 2002;166:159-65, 12119227. CrossrefGoogle Scholar7 Imadojemu VA, Gleeson K, Gray KS, Sinoway LI, Leuenberger UAObstructive sleep apnea during sleep is associated with peripheral vasoconstriction. Am J Respir Crit Care Med; 2002;165:61-6, 11779731. CrossrefGoogle Scholar8 Sajkov D, Wang T, Saunders NA, Bune AJ, McEvoy RDContinuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med; 2002;166:152-8, 11790646. CrossrefGoogle Scholar9 Amin RS, Kimball TR, Bean JAet al.Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med; 2002;165:1395-9, 12016102. CrossrefGoogle Scholar10 Rebuffè-Scrive M, Mårin P, Björntorp PEffect of testosterone on abdominal adipose tissue in men. Int J Obes; 1991;15:791-5, 1778664. Google Scholar11 Barceló A, Barbé F, Llompart Eet al.Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med; 2004;117:118-21, 15234648. CrossrefGoogle Scholar12 Barceló A, Barbé F, de la Peña Met al.Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax; 2008;63:946-50, 18535117. CrossrefGoogle Scholar13 Bhushan B, Guleria R, Misra A, Pandey RM, Luthra K, Vikram NKObstructive sleep apnoea correlates with C-reactive protein in obese Asian Indians. Nutr Metab Cardiovasc Dis; 2009;19:184-9, 18805681. CrossrefGoogle Scholar14 Can M, Açikgöz S, Mungan Get al.Serum cardiovascular risk factors in obstructive sleep apnea. Chest; 2006;129:233-7, 16478836. CrossrefGoogle Scholar15 Cofta S, Wysocka E, Michalak S, Piorunek T, Batura-Gabryel H, Torlinski LEndothelium-derived markers and antioxidant status in the blood of obstructive sleep apnea males. Eur J Med Res; 2009;14Suppl 4:49-52, 20156725. CrossrefGoogle Scholar16 Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JPObstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J; 2004;25:735-41, 15120883. CrossrefGoogle Scholar17 Drager LF, Bortolotto LA, Maki-Nunes Cet al.The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome. Atherosclerosis; 2010;208:490-5, 19762024. CrossrefGoogle Scholar18 Gambineri A, Pelusi C, Pasquali RTestosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J Endocrinol Invest; 2003;26:493-8, 12952360. CrossrefGoogle Scholar19 Gasa M, Salord N, Fortuna AMet al.Obstructive sleep apnoea and metabolic impairment in severe obesity. Eur Respir J; 2011;38:1089-97, 21622590. CrossrefGoogle Scholar20 Gruber A, Horwood F, Sithole J, Ali NJ, Idris IObstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol; 2006;5:22, 17078884. CrossrefGoogle Scholar21 Guill S, Hargens T, Nickols-Richardson Set al.Early evidence of increased risk for metabolic syndrome in young men with latent obstructive sleep apnea. Metab Syndr Relat Disord; 2010;8:33-8, 19943797. CrossrefGoogle Scholar22 Iesato K, Tatsumi K, Saibara Tet al.Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ J; 2007;71:1293-8, 17652898. CrossrefGoogle Scholar23 Ip MS, Lam KS, Ho C, Tsang KW, Lam WSerum leptin and vascular risk factors in obstructive sleep apnea. Chest; 2000;118:580-6, 10988175. CrossrefGoogle Scholar24 Kono M, Tatsumi K, Saibara Tet al.Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest; 2007;131:1387-92, 17494788. CrossrefGoogle Scholar25 Lin QC, Zhang XB, Chen GP, Huang DY, Din HB, Tang AZObstructive sleep apnea syndrome is associated with some components of metabolic syndrome in nonobese adults. Sleep Breath; 2012;16:571-8, 21681412. CrossrefGoogle Scholar26 McArdle N, Hillman D, Beilin L, Watts GMetabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med; 2007;175:190-5, 17068329. CrossrefGoogle Scholar27 Monneret D, Borel JC, Pepin JLet al.Pleiotropic role of IGF-I in obesity hypoventilation syndrome. Growth Horm IGF Res; 2010;20:127-33, 20005140. CrossrefGoogle Scholar28 Ozol D, Turkay C, Kasapoglu B, Karamanlı H, Yıldırım ZRelationship between components of metabolic syndrome and polysomnographic findings in obstructive sleep apnea. Metab Syndr Relat Disord; 2011;9:13-8, 21034272. CrossrefGoogle Scholar29 Panaree B, Chantana M, Wasana S, Chairat NEffects of obstructive sleep apnea on serum brain-derived neurotrophic factor protein, cortisol, and lipid levels. Sleep Breath; 2011;15:649-56, 20865453. CrossrefGoogle Scholar30 Peled N, Kassirer M, Shitrit Det al.The association of OSA with insulin resistance, inflammation and metabolic syndrome. Respir Med; 2007;101:1696-701, 17466499. CrossrefGoogle Scholar31 Salord N, Mayos M, Miralda R, Perez ARespiratory sleep disturbances in patients undergoing gastric bypass surgery and their relation to metabolic syndrome. Obes Surg; 2009;19:74-9, 18795382. CrossrefGoogle Scholar32 Sánchez-de-la-Torre M, Pierola J, Vidal Cet al.Non-synonymous polymorphism in the neuropeptide S precursor gene and sleep apnea. Sleep Breath; 2011;15:403-8, 20405330. CrossrefGoogle Scholar33 Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi PObesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med; 2007;8:12-7, 17157064. CrossrefGoogle Scholar34 Tan KC, Chow WS, Lam JCet al.MS HDL dysfunction in obstructive sleep apnea. Atherosclerosis; 2006;184:377-82, 15975582. CrossrefGoogle Scholar35 Trakada G, Steiropoulos P, Nena Eet al.Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome. Sleep Breath; 2009;13:349-55, 19360446. CrossrefGoogle Scholar36 Hozo SP, Djulbegovic B, Hozo IEstimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Method; 2005;5:13. CrossrefGoogle Scholar37 Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RBEvidence-based medicine – How to practice and teach EBM2nd edOxford: Churchill Livingstone173-75; 2000. Google Scholar38 Prospective Studies CollaborationBlood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet; 2007;370:1829-39, 18061058. CrossrefGoogle Scholar39 Di Angelantonio E, Sarwar N, Perry Pet al.Major lipids, apolipoproteins, and risk of vascular disease. JAMA; 2009;302:1993-2000, 19903920. CrossrefGoogle Scholar40 Baigent C, Blackwell L, Emberson Jet al.Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet; 2010;376:1670-81, 21067804. CrossrefGoogle Scholar41 Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins RN-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol; 2007;49:311-9, 17239712. CrossrefGoogle Scholar42 Cleland JGF, McMurray JJV, Kjekshus Jet al.CORONA Study GroupPlasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol; 2009;54:1850-9, 19892235. Google Scholar43 Adedayo AM, Olafiranye O, Smith Det al.Obstructive sleep apnea and dyslipidemia: evidence and underlying mechanism. Sleep Breath; 2014;18:13-8, 22903801. CrossrefGoogle Scholar44 Arnaud C, Dematteis M, Pepin JL, Baguet JP, Lévy PSemin Immunopathol; 2009;31:113-25, 19404644. CrossrefGoogle Scholar45 Nadeem R, Molnar J, Madbouly EMet al.Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med; 2013;9:1003-12, 24127144. LinkGoogle Scholar46 Klein RL, Ascencao JL, Mironova M, Huang Y, Lopes-Virella MFEffect of inflammatory cytokines on the metabolism of low-density lipoproteins by human vascular endothelial cells. Metabolism; 2001;50:99-106, 11172482. CrossrefGoogle Scholar47 Börgel J, Sanner BM, Bittlinsky Aet al.Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J; 2006;27:121-7, 16387944. CrossrefGoogle Scholar48 Quan SF, Budhiraja R, Clarke DPet al.Impact of treatment with continuous positive airway pressure (CPAP) on weight in obstructive sleep apnea. J Clin Sleep Med; 2013;9:989-93, 24127141. LinkGoogle Scholar49 Fava C, Dorigoni S, Dalle Vedove Fet al.Effect of continuous positive airway pressure (CPAP) on blood pressure in patients with obstructive sleep apnea/hypopnea. A systematic review and meta-analysis. Chest; 2013926[Epub ahead of print]. Google Scholar50 Weinstock TG, Wang X, Rueschman Met al.A controlled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea. Sleep; 2012;35:617-25B, 22547887. CrossrefGoogle Scholar51 Mota PC, Drummond M, Winck JC, Santos AC, Almeida J, Marques JAAPAP impact on metabolic syndrome in obstructive sleep apnea patients. Sleep Breath; 2011;15:665-72, 20862557. CrossrefGoogle ScholarAPPENDIXFigure A1: Total cholesterol, standardized difference in means, OSA versus controlsDownload FigureFigure A2: LDL cholesterol, standardized difference in means, OSA versus controlsDownload FigureFigure A3: HDL cholesterol, standardized difference in means, OSA versus controlsDownload FigureFigure A4: Triglycerides, standardized difference in means, OSA versus controlsDownload FigureFigure A5: TC sensitivity analysisDownload FigureFigure A6: LDL sensitivity analysisDownload FigureFigure A7: HDL sensitivity analysisDownload FigureFigure A8: TG sensitivity analysisDownload Figure Previous article Next article FiguresReferencesRelatedDetailsCited bySleep bruxism is highly prevalent in adults with obstructive sleep apnea: a large-scale polysomnographic studyLi D, Kuang B, Lobbezoo F, de Vries N, Hilgevoord A and Aarab G Journal of Clinical Sleep Medicine, Vol. 19, No. 3, (443-451), Online publication date: 1-Mar-2023. Mendelian randomization reveals no associations of genetically-predicted obs" @default.
• W2068239602 created "2016-06-24" @default.
• W2068239602 creator A5029304779 @default.
• W2068239602 creator A5039470619 @default.
• W2068239602 creator A5043766633 @default.
• W2068239602 creator A5047627526 @default.
• W2068239602 creator A5050487156 @default.
• W2068239602 creator A5060050661 @default.
• W2068239602 creator A5073128741 @default.
• W2068239602 creator A5085511204 @default.
• W2068239602 date "2014-05-15" @default.
• W2068239602 modified "2023-10-16" @default.
• W2068239602 title "Effect of Obstructive Sleep Apnea Hypopnea Syndrome on Lipid Profile: A Meta-Regression Analysis" @default.
• W2068239602 cites W1537972189 @default.
• W2068239602 cites W1607804102 @default.
• W2068239602 cites W1788205751 @default.
• W2068239602 cites W1930861070 @default.
• W2068239602 cites W1945958562 @default.
• W2068239602 cites W1967177766 @default.
• W2068239602 cites W1973510642 @default.
• W2068239602 cites W1990779521 @default.
• W2068239602 cites W1992997045 @default.
• W2068239602 cites W1995398545 @default.
• W2068239602 cites W2012882995 @default.
• W2068239602 cites W2017797032 @default.
• W2068239602 cites W2018804515 @default.
• W2068239602 cites W2021765316 @default.
• W2068239602 cites W2023535377 @default.
• W2068239602 cites W2027608461 @default.
• W2068239602 cites W2041131149 @default.
• W2068239602 cites W2044790794 @default.
• W2068239602 cites W2052086695 @default.
• W2068239602 cites W2054536805 @default.
• W2068239602 cites W2055895901 @default.
• W2068239602 cites W2061192069 @default.
• W2068239602 cites W2081226646 @default.
• W2068239602 cites W2085698266 @default.
• W2068239602 cites W2086320912 @default.
• W2068239602 cites W2087035336 @default.
• W2068239602 cites W2087225497 @default.
• W2068239602 cites W2105613623 @default.
• W2068239602 cites W2108315906 @default.
• W2068239602 cites W2117765532 @default.
• W2068239602 cites W2118979966 @default.
• W2068239602 cites W2122384838 @default.
• W2068239602 cites W2127427274 @default.
• W2068239602 cites W2130385885 @default.
• W2068239602 cites W2136372593 @default.
• W2068239602 cites W2138140735 @default.
• W2068239602 cites W2139704316 @default.
• W2068239602 cites W2142403514 @default.
• W2068239602 cites W2142595196 @default.
• W2068239602 cites W2144537612 @default.
• W2068239602 cites W2147943031 @default.
• W2068239602 cites W2153495443 @default.
• W2068239602 cites W2157925799 @default.
• W2068239602 cites W2164089346 @default.
• W2068239602 cites W2333343699 @default.
• W2068239602 cites W2335449614 @default.
• W2068239602 cites W2408112907 @default.
• W2068239602 cites W2431832189 @default.
• W2068239602 cites W2785563066 @default.
• W2068239602 doi "https://doi.org/10.5664/jcsm.3690" @default.
• W2068239602 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4046360" @default.
• W2068239602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24910548" @default.
• W2068239602 hasPublicationYear "2014" @default.
• W2068239602 type Work @default.
• W2068239602 sameAs 2068239602 @default.
• W2068239602 citedByCount "107" @default.
• W2068239602 countsByYear W20682396022014 @default.
• W2068239602 countsByYear W20682396022015 @default.
• W2068239602 countsByYear W20682396022016 @default.
• W2068239602 countsByYear W20682396022017 @default.
• W2068239602 countsByYear W20682396022018 @default.
• W2068239602 countsByYear W20682396022019 @default.
• W2068239602 countsByYear W20682396022020 @default.
• W2068239602 countsByYear W20682396022021 @default.
• W2068239602 countsByYear W20682396022022 @default.
• W2068239602 countsByYear W20682396022023 @default.
• W2068239602 crossrefType "journal-article" @default.
• W2068239602 hasAuthorship W2068239602A5029304779 @default.
• W2068239602 hasAuthorship W2068239602A5039470619 @default.
• W2068239602 hasAuthorship W2068239602A5043766633 @default.
• W2068239602 hasAuthorship W2068239602A5047627526 @default.
• W2068239602 hasAuthorship W2068239602A5050487156 @default.
• W2068239602 hasAuthorship W2068239602A5060050661 @default.
• W2068239602 hasAuthorship W2068239602A5073128741 @default.
• W2068239602 hasAuthorship W2068239602A5085511204 @default.
• W2068239602 hasBestOaLocation W20682396021 @default.
• W2068239602 hasConcept C111919701 @default.
• W2068239602 hasConcept C124936440 @default.
• W2068239602 hasConcept C126322002 @default.
• W2068239602 hasConcept C164705383 @default.
• W2068239602 hasConcept C2775841894 @default.
• W2068239602 hasConcept C2776006263 @default.
• W2068239602 hasConcept C2777711342 @default.
• W2068239602 hasConcept C2777935920 @default.
• W2068239602 hasConcept C2778205975 @default.

• next